Diagnostic value of placental growth factor and soluble fms-like tyrosine kinase-1 as pre-eclampsia markers

Иванец, Т. Ю.; Тютюнник, В. Л.; Амирасланов, Э. Ю.; Ivanets, T. Yu.; Alekseeva, M. L.; Kan, Nai Wen; Tyutyunnik, Tyutyunnik V.L.; Amiraslanov, E. Yu.; Nasonova, D. M.; Fanchenko, N. D.

doi:10.17116/repro2015214129-133

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the diagnostic criteria for the severity of preeclampsia is the sFlt-1/PlGF ratio (Baranovskaya 2018, Ivanets et al 2012, Ivanets et al 2013, Ivanets et al 2015. sFlt-1 is a variant of the vascular endothelial growth factor receptor (VEGFR-1).…”

Section: Resultsmentioning

confidence: 99%

“…Resveratrol reduces the risk of thrombosis in experimental liver cirrhosis, normalizing platelet function (Xu et al 2016). Resveratrol has pronounced positive effects in preeclampsia in humans and in experiment (Tenório et al 2018, Bariani et al 2017, Ivanets et al 2015. The ability of resveratrol under experimental conditions to reduce inflammation induced by lipopolysaccharides, and to prevent preterm labor was found in (Bariani et al 2017).…”

Section: Resultsmentioning

confidence: 99%

“…Earlier in our laboratory, the endothelioprotective properties of resverаtrol and nicorandil were investigated (Kochkarov 2009, Stupakova et al 2018, which can activate K + ATP channels ( Novaković et al 2015, Tanaka et al 2010, therefore they were considered to be the most promising for carrying out the present research. In addition, when they were used, a pronounced effect was observed when correcting morphofunctional disorders under conditions of ADMA-like preeclampsia (Ivanets et al 2015).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

Ступакова¹,

Лазарева²,

Гуреев³

et al. 2019

RRP

View full text Add to dashboard Cite

Introduction. Preeclampsia is a formidable disease of the second half of pregnancy, leading to severe complications, including disability and even death. Many authors have recognized the correlation between the severity of preeclampsia and the degree of disturbances in the hemostasis system. In this regard, the objective of this study was to assess inhibition of platelet aggregation and the possibility of its correction with resverаtrol and nicorandil. Materials and methods. The study was performed on 250 mature white Wistar female rats weighing 250–300 g. The platelet aggregation induced by ADP, collagen, ristomycin, adrenaline was determined, as well as PTT, TT, aPTT, fibrinogen, and the clotting time. Results and discussion. Introduction of resverаtrol and nicorandil resulted in a decrease in thrombocyte aggregation capacity from 53.8 ± 2.60% to 22.1 ± 1.25% and 37.1 ± 1.79%, respectively, when using ADP as an inducer. The clotting time was from 841 ± 42 s up to 1135 ± 33 s and 1034 ± 26 s, respectively. In addition, there was an increase in temporal parameters of plasma-coagulation hemostasis and a decrease in plasma fibrinogen content. The use of glibenclamide resulted in partial cancellation of the positive effects of resverаtrol and nicorandil, with an increase in platelet aggregation to 28.9 ± 1.8% and 43.9 ± 1.2% when using ADP as an inducer and a decrease in the thrombosis time to 988 ± 26 s and 950 ± 22 s, respectively. Conclusion. In animals with experimental preeclampsia, there were disturbances in the hemostasis system, comparable to those in the clinical situation. The use of resverаtrol and nicorandil leads to a pronounced correction of hemostasis parameters. The positive effects of the studied pharmacological agents are mediated by several mechanisms, including K+ATP channels.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

Ступакова¹,

Лазарева²,

Гуреев³

et al. 2019

RRP

View full text Add to dashboard Cite

show abstract

Hyperprolactinemia of various genesis in premenopause: effect on cardiovascular risks, a practical aspect

Smirnov1,

Shapovalova,

Ivanov

et al. 2024

General Physician

View full text Add to dashboard Cite

The pathological aspects of hyperprolactinemia have been well studied to date and primarily affect changes in the reproductive system. Regardless of the genesis of hyperprolactinemia, negative changes include, first of all, dysmenorrhea and hyperan drogenism. Changes in the mammary glands include galactorrhea, mastopathy, and the development of breast cancer. The pathological effects of hyperprolactinemia on other organs and systems, including the cardiovascular system, have been studied less. Few existing studies suggest that elevated prolactin levels can potentially affect cardiovas cular risks and provoke myocardial remodeling, arterial hypertension, hyperhomocys teinemia, and disorders of the plasma lipid profile. Menopausal women are particularly vulnerable in this regard, as the cardioprotective role of estrogens is significantly re duced during this period. In this article, we examined the effect of hyperprolactinemia on the formation of cardiovascular disorders in premenopausal women. The purpose of the study was to evaluate the effect of hyperprolactinemia on the genesis of cardiovascular pathology in premenopausal women. Materials and methods: three groups of premenopausal patients were examined. The patients of the first group (n=26) had previously been diagnosed with pituitary adenoma and were treated with cabergoline, maintaining the target prolactin level for at least two years. According to pituitary MRI, prolactinoma and elevated prolactin levels were de tected in the patients of the second group (n=21), but these patients did not take prolac tin-lowering therapy for various reasons. The third group consisted of the patients with idiopathic hyperprolactinemia who did not receive prolactin-lowering therapy (n=19). The patients of all three groups underwent general clinical examination, determination of the daily blood pressure profile, ECG, echocardiography, determination of the level of lipidogram, homocysteine, and other markers of cardiovascular risk. The results of the study showed that regardless of its genesis, pathological hyperprolactinemia influences the development of cardiovascular pathology in premenopausal women.

show abstract

Diagnostic value of placental growth factor and soluble fms-like tyrosine kinase-1 as pre-eclampsia markers

Cited by 2 publications

References 8 publications

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

Hyperprolactinemia of various genesis in premenopause: effect on cardiovascular risks, a practical aspect

Contact Info

Product

Resources

About